<DOC>
	<DOCNO>NCT01058434</DOCNO>
	<brief_summary>This study evaluate safety efficacy TKI258 patient relapse refractory multiple myeloma</brief_summary>
	<brief_title>Safety Efficacy TKI258 Relapsed Refractory Multiple Myeloma Patients , Who Are With Without ( 4 ; 14 ) Chromosomal Translocation</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>1 . Cytopathologically histologically confirm diagnosis multiple myeloma previously require systemic treatment . 2 . Evidence relapse refractory disease document prior treatment history . ( Refractory myeloma define disease nonresponsive salvage therapy , progress within 60 day last therapy . Relapsed myeloma define previously treat myeloma period offtherapy require initiation salvage therapy . Detailed definition provide PTS1 ) 3 . Have receive least 2 prior treatment regimens multiple myeloma include chemotherapy , autologous transplantation , immunotherapy , investigational agent . Preplanned induction , follow transplant maintenance consider one regimen . 4 . Presence measurable disease define least one follow ; Serum Mprotein ≥ 1g/dL ( measurable disease ) Urine Mprotein ≥ 200mg/24 hour protein electrophoresis ( measurable disease ) 1 . Patients nonsecretory , oligosecretory , multiple myeloma . 2 . Patients symptomatic amyloidosis , plasma cell leukemia . 3 . Patients receive allogeneic stem cell transplantation show evidence active graftversushost disease require immunosuppressive therapy . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Multiple myeloma</keyword>
	<keyword>relapse</keyword>
	<keyword>refractory</keyword>
	<keyword>( 4 ; 14 )</keyword>
	<keyword>FGFR3</keyword>
</DOC>